The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type

Luca Tomisti, Giuseppe Rossi, Luigi Bartalena, Enio Martino and Fausto Bogazzi

Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Ospedale Cisanello, Via Paradisa, 2, 56124 Pisa, Italy, 1Endocrine Unit, Department of Clinical and Experimental Medicine, University of Insubria, 21100 Varese, Italy and 2Unit of Epidemiology and Biostatistics, Institute of Clinical Physiology, National Research Council, 56184 Pisa, Italy

Correspondence should be addressed to F Bogazzi
Email fausto.bogazzi@med.unipi.it or fbogazzi@hotmail.com

Abstract

Objective: Considering the different pathogenic mechanisms of the two main forms of amiodarone-induced thyrotoxicosis (AIT), we ascertained whether this results in a different onset time as well.

Design and methods: We retrospectively analyzed the clinical records of 200 consecutive AIT patients (157 men and 43 women; mean age 62.2 ± 12.6 years) referred to our Department from 1987 to 2012. The onset time of AIT was defined as the time elapsed from the beginning of amiodarone therapy and the first diagnosis of thyrotoxicosis, expressed in months. Factors associated with the onset time of AIT were evaluated by univariate and multivariate analyses.

Results: The median onset time of thyrotoxicosis was 3.5 months (95% CI 2–6 months) in patients with type 1 AIT (AIT1) and 30 months (95% CI 27–32 months, P < 0.001) in those with type 2 AIT (AIT2). Of the total number of patients, 5% with AIT1 and 23% with AIT2 (P = 0.007) developed thyrotoxicosis after amiodarone withdrawal. Factors affecting the onset time of thyrotoxicosis were the type of AIT and thyroid volume (TV).

Conclusions: The different pathogenic mechanisms of the two forms of AIT account for different onset times of thyrotoxicosis in the two groups. Patients with preexisting thyroid abnormalities (candidate to develop AIT1) may require a stricter follow-up during amiodarone therapy than those usually recommended. In AIT1, the onset of thyrotoxicosis after amiodarone withdrawal is rare, while AIT2 patients may require periodic tests for thyroid function longer after withdrawing amiodarone.

Introduction

Amiodarone-induced thyrotoxicosis (AIT) develops in ~15% of patients under amiodarone therapy (1, 2). Two main forms of AIT may occur: type 1 is a form of iodine-induced hyperthyroidism occurring in patients with underlying thyroid abnormalities, and type 2 is a destructive thyroiditis mainly due to direct cytotoxic effects of amiodarone on thyroid follicular cells of a normal thyroid gland (1, 3, 4, 5). The prevalence of the two main forms of AIT has changed over the last 30 years in Italy with a current predominance of the type 2 AIT (AIT2) (6).

Occurrence of AIT is usually considered to be unpredictable, often sudden, and explosive, occurring either early or long after initiation of amiodarone treatment. In a group of 58 patients, Trip et al. (7) observed that average duration of amiodarone treatment before AIT occurrence was ~3 years, with a probability of 2.5% after 18 months and 33.5% after 48 months. In addition, Ahmed et al. (8) have recently reported an AIT incidence rate per 100 persons/year of 1.9 in a series of 303 patients taking amiodarone. Other small prospective studies described the onset of AIT after 12–47 months of amiodarone therapy (9, 10). AIT may also develop months after drug withdrawal, because of tissue storage of the drug and its metabolites and their slow release into the circulation.

Owing to the different pathogenic mechanisms of the two forms of AIT, we aimed at evaluating whether AIT1 and AIT2 may have different onset times in a large series of patients. This information might be useful in clinical
practice for planning a different surveillance program of thyroid function.

Materials and methods

Study design

We retrospectively analyzed the clinical records of AIT patients referred to the Department of Clinical and Experimental Medicine, Endocrinology Section, University of Pisa, from January 1987 to December 2012.

Each patient gave her/his written informed consent, at the first clinical visit at our Department, for the use of anonymous data for research purpose. The Internal Review Board of our Department approved the study.

Subjects and diagnosis of AIT

A total of 200 consecutive AIT patients (157 men and 43 women; mean (±s.d.), age 62.2 ± 12.6 years, range 24–87 years) were included in the study.

Diagnosis of AIT was based on clinical grounds (signs and symptoms of thyrotoxicosis) and laboratory findings, including increased serum free thyroxine (FT4) and free tri-iodothyronine (FT3) concentrations, undetectable serum TSH levels, and increased urinary iodine excretion (UIE). Diagnosis of AIT2 was based on the following criteria (1): normal or slightly increased TV without nodules (?1 cm) at conventional ultrasonography, absent hypervascularity at color-flow Doppler sonography, absence of circulating thyroid-directed autoantibody (anti-thyroglobulin (TgAb), anti-thyroid peroxidase (TPOAb), anti-TSH receptor (TRAb)), and low/undetectable thyroid radiiodine uptake (RAIU) values (<5% at 24 h), as reported previously (11, 12).

The remaining subjects, including patients with Graves’ disease, toxic adenoma, and multinodular goiter, did not meet the above criteria and were classified as type 1 AIT (AIT1). For the purpose of this study, all non-AIT2 patients were designated as AIT1, as reported previously (6). These criteria were applied retrospectively to patients diagnosed with AIT before 1990, when differentiation of the two main types of AIT had not yet been clearly established (6).

Clinical and biochemical findings of the two groups are given in Table 1.

Time definitions

Onset time of AIT was defined as the period elapsed from initiation of amiodarone therapy and first diagnosis of thyrotoxicosis. Onset time after amiodarone withdrawal was defined as the period elapsed from the withdrawal of amiodarone therapy and first diagnosis of thyrotoxicosis in patients who developed thyrotoxicosis after amiodarone discontinuation.

Thyroid status

Serum FT4, FT3 (Vitros Immunodiagnostics, The Broadway, Amersham), TSH (Immulite 2000, third generation TSH; Diagnostic Products Corp., Los Angeles, CA, USA),

<p>| Table 1 | Clinical and biochemical features of the study groups. Data are expressed as mean ± s.d. Normal values in our laboratory are as follows: FT4, 7–17 pg/ml; FT3, 2.7–4.5 pg/ml; TSH, 0.4–3.4 mU/l; TPOAb, &lt;10 IU/ml; and 3rd and 24th h RAIU, in our area, 15–30 and 30–45% respectively. To convert serum FT4 and FT3 values from pg/ml to pmol/l, multiply by 1.29 and 1.54 respectively. |</p>
<table>
<thead>
<tr>
<th>Variable</th>
<th>AIT1 (n=42)</th>
<th>AIT2 (n=158)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female/male)</td>
<td>11/31</td>
<td>32/126</td>
<td>0.41</td>
</tr>
<tr>
<td>Age (years)</td>
<td>65.3 ± 10.6</td>
<td>61.4 ± 13</td>
<td>0.07</td>
</tr>
<tr>
<td>BSA (m²)</td>
<td>1.85 ± 0.23</td>
<td>1.88 ± 0.21</td>
<td>0.52</td>
</tr>
<tr>
<td>BMI</td>
<td>26.1 ± 4.6</td>
<td>25.4 ± 3.9</td>
<td>0.35</td>
</tr>
<tr>
<td>Basal FT4 (pg/ml)</td>
<td>28.2 ± 15.3</td>
<td>41.7 ± 16.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Basal FT3 (pg/ml)</td>
<td>7.2 ± 4.7</td>
<td>10.2 ± 5.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FT4/FT3</td>
<td>4.2 ± 2.2</td>
<td>4.4 ± 1.3</td>
<td>0.50</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>1.00</td>
</tr>
<tr>
<td>TPOAb (IU/ml)</td>
<td>138 ± 384</td>
<td>&lt;10</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>UIE (µg/l)</td>
<td>5769 ± 10999</td>
<td>7967 ± 8045</td>
<td>0.24</td>
</tr>
<tr>
<td>TG (ng/ml)</td>
<td>218.3 ± 492.2</td>
<td>136.1 ± 203.9</td>
<td>0.32</td>
</tr>
<tr>
<td>3rd h RAIU (%)</td>
<td>7.1 ± 8</td>
<td>1.5 ± 1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>24th h RAIU (%)</td>
<td>12.8 ± 13.3</td>
<td>1.1 ± 1.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TV (ml)</td>
<td>56.7 ± 39.7</td>
<td>19.6 ± 8.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TV norm (ml/m²)</td>
<td>30.5 ± 20.1</td>
<td>10.5 ± 4.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CFDS pattern (0/1/2/3)</td>
<td>3/11/23/5</td>
<td>154/40/0/0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Duration of amiodarone treatment (months)</td>
<td>9.9 ± 11.8</td>
<td>28.7 ± 16.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Daily dose of amiodarone (mg)</td>
<td>193 ± 38</td>
<td>192 ± 54</td>
<td>0.96</td>
</tr>
<tr>
<td>Cumulative dose of amiodarone (g)</td>
<td>46.8 ± 31.7</td>
<td>134.4 ± 108.8</td>
<td>0.001</td>
</tr>
<tr>
<td>AIT post AMIO (%)</td>
<td>2/40 (4.76)</td>
<td>36/122 (22.8)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Basal FT4 and basal FT3, serum thyroid hormone concentrations at diagnosis; UIE, urinary iodine excretion; TG, serum thyroglobulin; 3rd and 24th h RAIU, 3rd and 24th h thyroid radiiodine uptake; BSA, body surface area calculated using the Mosteller formula, as described previously; TV, thyroid volume estimated by ultrasonography; TV norm, normalized thyroid volume obtained by dividing thyroid volume by body surface area; CFDS pattern, color-flow Doppler sonography pattern expressed as the number of patients having pattern 0/1/2/3; AIT after AMIO, number of patients (and percentage) developing AIT after amiodarone withdrawal.
TG (Access Immunoassay Systems; Beckman Coulter, Inc., Brea, CA, USA), TRAb (TRAK human; Brahms, Hennigsdorf, Germany), TgAb (AIA-Pack TgAb; Tosoh, Tokyo, Japan), and TPOAb (AIA-Pack TPOAb; Tosoh) were assayed using commercial kits. Normal values in our laboratories are as follows: FT₄, 7–17 pg/ml (9.0–22.0 pmol/l); FT₃, 2.7–4.5 pg/ml (4.2–7.0 pmol/l); TSH, 0.4–3.4 mU/l; TRAb, >1 U/l; TgAb, >30 IU/ml; and TPOAb, >10 IU/ml.

Random morning urinary samples were collected for iodine measurements using an autoanalyzer apparatus (Technicon, Rome, Italy). Median UIE in our area is 110 mg/l.

Thyroid ultrasound and RAIU

TV was measured by ultrasonography and calculated by the ellipsoid model (width×length×thickness×0.52 for each lobe) as described previously (13, 14). TV was normalized by body surface area (TV norm) calculated using the Mosteller formula (BSA (m²)=√height (m)×weight (kg)/3600) (15), because, as reported previously (16), BSA accounts for the main variations in TVs, including sex-related differences; normal values in our areas are 3.5–13 ml/m².

Thyroid RAIU was measured at 3 and 24 h after the administration of a tracer dose (50 μCi) of ¹³¹I. The normal 3 and 24 h RAIU values in our area are 10–20 and 30–45% respectively.

Statistical analysis

Results are expressed as mean±S.D. for quantitative data and percentage for categorical data. The comparison between the two study groups (AIT1 vs AIT2) for clinical and biochemical features was performed by the Wilcoxon rank-sum test for quantitative variables and by Fisher’s exact test for categorical variables. The onset time of AIT was analyzed by the Kaplan–Mayer survival curve and the comparison between groups was performed by the log-rank test. Factors associated with onset time were evaluated by univariate and multivariate analyses using the Cox regression model. Hazard ratio (HR) and 95% CI were also reported. A two-sided P value of <0.05 was considered statistically significant. Statistical analysis was performed using the JMP 4 (SAS Institute, Inc., Cary, NC, USA) software.

Results

Out of 200 patients evaluated in this study, 42 (21%) were diagnosed with AIT1 and 158 (79%) with AIT2. The clinical and biochemical features of the two groups of patients are given in Table 1. As expected, patients with AIT2 had lower 3 and 24-h RAIU values and a smaller TV than those with AIT1. In addition, patients with AIT2 had significantly higher serum thyroid hormone concentrations (FT₄ 41.7±16.4 pg/ml and FT₃ 10.2±5.2 pg/ml) than those with AIT1 (FT₄ 28.2±15.3 pg/ml and FT₃ 7.2±4.7 pg/ml, P<0.001 and P<0.001 respectively). Eight patients with AIT1 had Graves’ disease, six a toxic adenoma, and 28 a multinodular goiter.

Median onset time of thyrotoxicosis in the AIT1 group was 3.5 months (range 1–61 months) and 30 months in AIT2 group (range 1–95 months, log-rank <0.001, Fig. 1). Distribution of onset time of AIT in the two groups of patients is shown in Fig. 2.

Out of 200 patients, 38 (19%) developed thyrotoxicosis after amiodarone withdrawal: two patients in the AIT1 group (4.8%) and 36 patients in the AIT2 group (22.9%, P=0.007). The two patients with AIT1 developed thyrotoxicosis at 1 and 12 months (median time 6.5 months) after the withdrawal of amiodarone. The time elapsed from the withdrawal of amiodarone therapy and the first diagnosis of thyrotoxicosis in the AIT2 group (median time 5.5 months, range 1–18 months) is summarized in Fig. 3. In the AIT2 group, no difference was found between patients developing thyrotoxicosis before or after amiodarone withdrawal in TV, normalized TV, BMI, and sex, whereas patients developing thyrotoxicosis after amiodarone withdrawal were significantly younger (56.8±11.9 vs 62.8±13 years respectively; P=0.014). In addition, the onset time of thyrotoxicosis...
did not significantly differ in patients who developed AIT during amiodarone therapy or after therapy withdrawal (median time 31 months, range 1–200 months, and median time 26 months, range 2–63 months respectively; log-rank $P = 0.066$).

Factors affecting the onset time of thyrotoxicosis were evaluated by the univariate and multivariate analyses, as reported in Table 2. In the univariate analysis, a shorter onset time was related to AIT1 ($P < 0.0001$) and to a larger normalized TV ($P < 0.0001$). When patients were divided based on the type of AIT, the univariate analysis confirmed the significant effect of the normalized TV on the onset time of thyrotoxicosis (HR 1.01, 95% CI 1.00–1.03, $P = 0.04$ in the AIT1 group and HR 1.05, 95% CI 1.01–1.09, $P = 0.01$ in the AIT2 group).

After adjusting for age, sex, and BMI, in the multivariate analysis, the type of AIT and the normalized TV were confirmed as the main independent factors affecting the onset time of thyrotoxicosis with a HR of 2.88 (95% CI 1.76–4.55, $P < 0.0001$) and 1.03 (95% CI 1.01–1.04, $P < 0.0001$) per unit of increment respectively. No interaction was found between the type of AIT and normalized TV ($P = 0.42$).

**Discussion**

Onset of thyrotoxicosis during amiodarone therapy is usually considered to be unpredictable (1, 3, 7) and has been reported to occur at any time during therapy as well as after drug withdrawal. However, no studies have so far investigated as to whether differences exist in the onset time of the two main forms of AIT.

The present retrospective study of a large cohort of patients is the first report of a significant difference in the onset time of thyrotoxicosis of the two forms of AIT. The time elapsed from initiation of amiodarone therapy and occurrence of thyrotoxicosis was much shorter in AIT1 than in AIT2, the median time being 3.5 and 30 months respectively.

This observation is consistent with previous limited observations in small series and the different pathogenic mechanisms of the two forms of AIT (6, 12, 17). AIT1 is a form of iodine-induced hyperthyroidism arising in a thyroid gland with underlying functional autonomy; in these patients, iodine load may rapidly trigger an increased thyroid hormone synthesis. Conversely, AIT2, being a destructive thyroiditis due to a direct cytotoxic effect of amiodarone or iodine (1, 3, 18, 19), may imply that a high intrathyroid drug concentration may be reached before the damage of thyroid follicular cells becomes evident at a clinical level (20).
However, AIT2 may also have an abrupt and explosive onset at any time during amiodarone therapy (21). In fact, although the mean onset time was 30 months in AIT2 patients, ~15% of subjects developed thyrotoxicosis after <12 months of amiodarone therapy.

In addition, we observed that ~20% of AIT2 patients developed thyrotoxicosis after amiodarone withdrawal, probably due to the long storage time and the slow release of amiodarone and its main metabolite, desethylamiodarone, from the adipose tissue, which prolong and maintain exposure of the thyroid gland to amiodarone. This is in keeping with the observation that onset time of thyrotoxicosis in this subset of patients did not differ significantly from that of patients who developed thyrotoxicosis during amiodarone therapy. This event was rarely observed in AIT1 (<5%), which is associated with an earlier occurrence of thyrotoxicosis.

Despite the clear-cut difference in the average onset time of AIT1 and AIT2, there was a partial overlap between the two forms. A possible reason for the presence of a longer onset time in a small subset of AIT1 patients may be a concomitant destructive process (mixed forms) accountable for a longer onset time. However, ~70% of AIT1 patients but only 5% of AIT2 patients developed AIT within 6 months. At variance, in 70% of AIT2 patients, thyrotoxicosis developed after 2 years, while only 10% of AIT1 has such a long onset time. The interval between initiation of amiodarone therapy and occurrence of AIT, nevertheless, cannot be used, alone, to distinguish the two forms of AIT in individual patients.

Another independent determinant of the onset time of thyrotoxicosis was the TV. We have previously reported that the normalized TV is an independent factor affecting the response to glucocorticoid therapy in AIT2 patients (11). In this study, we have found that a larger TV was related to a shorter onset time of thyrotoxicosis, confirming that the thyroid size plays a role in development and severity of AIT. It is noteworthy that the TV is calculated at the moment of the diagnosis of AIT. This is a limitation of our study due to its retrospective design. However, no data regarding modification of the TV in patients under amiodarone therapy have been currently reported. Thus, being so we have considered the TV, estimated at the time of diagnosis of AIT, to be a good proxy for the basal TV. As a matter of fact, a prospective study by Silva et al. (22) did not find any correlation among the time of use, the daily dose and the cumulative dose of amiodarone, and the detection of goiter in a subset of patients taking amiodarone because of Chagas disease. This information may support the concept that TV should not be significantly affected by the amiodarone therapy.

It has been previously observed that a lower BMI may be an independent risk factor for the development of AIT (23). However, our study failed to find a relationship between the onset time of thyrotoxicosis and BMI. It is worth noting that patients described in the study by Stan et al. (23) had congenital cardiomyopathy and a normal to low BMI, at variance with patients of the present series.

In conclusion, our data showed that patients with AIT1 have a shorter median onset time of thyrotoxicosis than those with AIT2. In patients under amiodarone therapy, evaluation of thyroid function is usually recommended at 6-month intervals (1, 2, 3, 24). Based on the present data, we suggest a closer follow-up (i.e. every 1–3 months) for the patients with preexisting thyroid abnormalities (autonomous multinodular goiter or latent Graves’ disease) who may develop AIT1.

By contrast, in patients with a normal thyroid gland we cannot provide a follow-up plan able to guarantee an early diagnosis of AIT because of the large variability of their onset time. In addition, the onset of thyrotoxicosis is often sudden and the clinical features of thyrotoxicosis may be atypical and mild, mainly in older patients. As a result, evaluation of thyroid function should be performed, at any time, in patients under amiodarone therapy showing an unexpected worsening of cardiac conditions and in patients, also taking warfarin therapy, showing an unexplained increased sensitivity to anticoagulant therapy (25).

However, in patients under amiodarone therapy showing no signs of thyrotoxicosis, we believe that a thyroid function test should be periodically performed because the diagnosis of thyrotoxicosis might be strongly delayed by the atypical clinical features often observed.
Finally, thyroid function should be monitored for at least 2 years after amiodarone withdrawal, particularly in patients without apparent thyroid abnormalities.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


Received 2 April 2014
Revised version received 30 May 2014
Accepted 16 June 2014